Qiang Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Qiang Ma has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Xiaolan Guo
Department of Clinical Laboratory, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
5 shared publications Lei Xu
Translational Medicine Research Center, North Sichuan Medical College, Nanchong, China
4 shared publicationsXiaowu Zhong
Translational Medicine Research Center, North Sichuan Medical College, Nanchong, China
3 shared publicationsYong Yang
Department of Clinical Laboratory, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
3 shared publicationsChongbo Liao
Department of Clinical Laboratory, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
2 shared publicationsJiang Zhu
Translational Medicine Research Center, North Sichuan Medical College, Nanchong, China
2 shared publications
Latest Publications
- Open Access
- 23 March 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17
Integrated analysis of Morusin inhibiting esophageal cancer via network pharmacology molecular dynamics simulation and in vitro validation
Esophageal cancer (EC) is a malignant tumor characterized by high incidence and mortality, and its complex pathogenesis necessitates the development of effective therapeutic strategies. In this study, we investigated the anti-cancer effects and underlying mechanisms of Morusin against EC using network pharmacology, molecular dynamics (MD) simulation, and in vitro experiments. Transcriptomic analysis identified 3,540 differentially expressed genes in EC as potential therapeutic targets, while potential targets of Morusin were predicted using the SWISSprediction database. The intersection analysis revealed 21 common genes, which may represent the key targets of Morusin in EC treatment. A protein–protein interaction (PPI) network was constructed using the STRING database and analyzed in Cytoscape 3.8.0, identifying MAPK3, PTGS2, and HSP90AA1 as core hub genes. GO enrichment analysis indicated that the biological processes involved in Morusin’s anti-EC activity mainly included peptidyl-serine phosphorylation, peptidyl-serine modification, and aging. The cellular components were primarily associated with focal adhesion, cell–substrate junction, and caveola, while the molecular functions were enriched in protein serine kinase activity, protein serine/threonine kinase activity, protein serine/threonine/tyrosine kinase activity, and MAP kinase kinase activity. KEGG pathway enrichment suggested that Morusin may exert its effects through the HIF-1 signaling pathway, prostate cancer, and serotonergic synapse pathways. Molecular docking and MD simulations demonstrated stable binding of Morusin to ERK1 (MAPK3) and MEK1. In vitro assays revealed that 10 µM Morusin markedly inhibited the proliferation of EC cells (KYSE150 and TE1) without significant cytotoxicity toward normal esophageal epithelial cells (Het-1 A). Furthermore, Transwell and wound-healing assays confirmed that Morusin suppressed EC cell migration and invasion. Western blot analysis showed that Morusin treatment decreased Bcl-2 expression and increased cleaved-caspase3/caspase3, cleaved-PARP/PARP, and Bax levels, accompanied by significant downregulation of p-MEK1/2, p-MAPK3, and p-ERK2. Collectively, these findings suggest that Morusin inhibits proliferation, migration, and invasion, and induces apoptosis in EC cells by suppressing the MAPK signaling pathway.
- 23 March 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17
Open AccessIntegrated analysis of Morusin inhibiting esophageal cancer via network pharmacology molecular dynamics simulation and in vitro validation
Esophageal cancer (EC) is a malignant tumor characterized by high incidence and mortality, and its complex pathogenesis necessitates the development of effective therapeutic strategies. In this study, we investigated the anti-cancer effects and underlying mechanisms of Morusin against EC using network pharmacology, molecular dynamics (MD) simulation, and in vitro experiments. Transcriptomic analysis identified 3,540 differentially expressed genes in EC as potential therapeutic targets, while potential targets of Morusin were predicted using the SWISSprediction database. The intersection analysis revealed 21 common genes, which may represent the key targets of Morusin in EC treatment. A protein–protein interaction (PPI) network was constructed using the STRING database and analyzed in Cytoscape 3.8.0, identifying MAPK3, PTGS2, and HSP90AA1 as core hub genes. GO enrichment analysis indicated that the biological processes involved in Morusin’s anti-EC activity mainly included peptidyl-serine phosphorylation, peptidyl-serine modification, and aging. The cellular components were primarily associated with focal adhesion, cell–substrate junction, and caveola, while the molecular functions were enriched in protein serine kinase activity, protein serine/threonine kinase activity, protein serine/threonine/tyrosine kinase activity, and MAP kinase kinase activity. KEGG pathway enrichment suggested that Morusin may exert its effects through the HIF-1 signaling pathway, prostate cancer, and serotonergic synapse pathways. Molecular docking and MD simulations demonstrated stable binding of Morusin to ERK1 (MAPK3) and MEK1. In vitro assays revealed that 10 µM Morusin markedly inhibited the proliferation of EC cells (KYSE150 and TE1) without significant cytotoxicity toward normal esophageal epithelial cells (Het-1 A). Furthermore, Transwell and wound-healing assays confirmed that Morusin suppressed EC cell migration and invasion. Western blot analysis showed that Morusin treatment decreased Bcl-2 expression and increased cleaved-caspase3/caspase3, cleaved-PARP/PARP, and Bax levels, accompanied by significant downregulation of p-MEK1/2, p-MAPK3, and p-ERK2. Collectively, these findings suggest that Morusin inhibits proliferation, migration, and invasion, and induces apoptosis in EC cells by suppressing the MAPK signaling pathway.
- Open Access
- 16 December 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1689663
Fedratinib reveals chemotherapeutic potential in esophageal squamous cell cancer
Background: Drug repurposing has emerged as a promising approach for discovering novel anticancer therapeutics. In this study, we systematically investigated the antitumor potential of fedratinib, a JAK2 inhibitor approved for myelofibrosis, against esophageal squamous cell carcinoma (ESCC) using integrated in vitro , in vivo , and patient-derived organoid (PDO) models. We further explored its underlying mechanisms of action. Methods: ESCC cell lines (Eca109 and KYSE150) were treated with fedratinib to evaluate its effects on proliferation, migration, apoptosis, and cell cycle distribution. Molecular changes were examined using RT-qPCR and Western blot analyses. Antitumor efficacy was further validated in subcutaneous xenograft models and ESCC PDOs. Mechanistic investigations included STAT3 overexpression and functional rescue experiments. Results: Fedratinib significantly inhibited ESCC cell proliferation and migration and induced cell cycle arrest at the G2/M phase while promoting apoptosis in vitro . It also suppressed tumor growth in xenograft models and showed consistent efficacy in PDOs. Mechanistically, fedratinib inhibited the activation of the JAK2/STAT3 signaling pathway and downregulated the expression of vimentin, survivin, and cyclin D1. Overexpression of STAT3 reversed these molecular alterations and diminished the functional effects of fedratinib. Similarly, ectopic expression of survivin, vimentin, or cyclin D1 partially rescued the phenotypic changes induced by fedratinib. Conclusion: Fedratinib exerts antitumor effects against ESCC in vitro , in vivo , and in patient-derived organoid models by suppressing the JAK2–STAT3 signaling axis and its downstream effectors, vimentin, survivin, and cyclin D1.
- 16 December 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1689663
Open AccessFedratinib reveals chemotherapeutic potential in esophageal squamous cell cancer
Background: Drug repurposing has emerged as a promising approach for discovering novel anticancer therapeutics. In this study, we systematically investigated the antitumor potential of fedratinib, a JAK2 inhibitor approved for myelofibrosis, against esophageal squamous cell carcinoma (ESCC) using integrated in vitro , in vivo , and patient-derived organoid (PDO) models. We further explored its underlying mechanisms of action. Methods: ESCC cell lines (Eca109 and KYSE150) were treated with fedratinib to evaluate its effects on proliferation, migration, apoptosis, and cell cycle distribution. Molecular changes were examined using RT-qPCR and Western blot analyses. Antitumor efficacy was further validated in subcutaneous xenograft models and ESCC PDOs. Mechanistic investigations included STAT3 overexpression and functional rescue experiments. Results: Fedratinib significantly inhibited ESCC cell proliferation and migration and induced cell cycle arrest at the G2/M phase while promoting apoptosis in vitro . It also suppressed tumor growth in xenograft models and showed consistent efficacy in PDOs. Mechanistically, fedratinib inhibited the activation of the JAK2/STAT3 signaling pathway and downregulated the expression of vimentin, survivin, and cyclin D1. Overexpression of STAT3 reversed these molecular alterations and diminished the functional effects of fedratinib. Similarly, ectopic expression of survivin, vimentin, or cyclin D1 partially rescued the phenotypic changes induced by fedratinib. Conclusion: Fedratinib exerts antitumor effects against ESCC in vitro , in vivo , and in patient-derived organoid models by suppressing the JAK2–STAT3 signaling axis and its downstream effectors, vimentin, survivin, and cyclin D1.
- Open Access
- 26 February 2025
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 210, 107051
Exploring the novel role and mechanistic insights of skeletal muscle relaxant cyclobenzaprine hydrochloride in esophageal squamous cell carcinoma treatment
- 26 February 2025
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 210, 107051
Open AccessExploring the novel role and mechanistic insights of skeletal muscle relaxant cyclobenzaprine hydrochloride in esophageal squamous cell carcinoma treatment
- Open Access
- 24 February 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-15
Pan‑cancer analysis of the oncogenic role of telomeric repeat binding factor 2 (TERF2) in human tumors and in vitro validation in gastric cancer by TERF2 knockdown
Background Telomeric repeat binding factor 2 (TERF2), a key component of the Shelterin complex, is crucial for maintaining telomere integrity and genome stability. While the involvement of TERF2 in tumorigenesis and progression has been documented, comprehensive pan-cancer analyses of TERF2 across different malignancies remain scarce. Methods In the present study, the expression, mutations, immune cell infiltration, and interacting genes of TERF2 were systematically evaluated through bioinformatics analysis, and in vitro experiments were performed to elucidate the functional roles of TERF2 in gastric cancer. Results The findings revealed that TERF2 was predominantly upregulated in cholangiocarcinoma (CHOL), diffuse large B-cell lymphoma (DLBC), pancreatic adenocarcinoma (PAAD), stomach adenocarcinoma (STAD), and thymoma (THYM), correlating with tumor progression. Amplification and mutations were identified as the primary alterations of TERF2, particularly associated with liver hepatocellular carcinoma (LIHC). Furthermore, TERF2 expression was linked to the infiltration of cancer-associated fibroblasts and immune cells in certain cancer types. Protein–protein interaction (PPI) analysis highlighted several genes associated with TERF2, including CTCF, DDX19A, MATR3, ZFP1, and ZFP90. Additionally, in vitro experiments demonstrated that TERF2 knockdown significantly suppressed the proliferation and migration of gastric cancer cells. Conclusions These results suggest that dysregulation and mutations of TERF2 are prevalent across various cancers, contributing to tumor immunity and acting as an oncogenic factor, thus positioning TERF2 as a potential therapeutic target in cancer treatment.
- 24 February 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-15
Open AccessPan‑cancer analysis of the oncogenic role of telomeric repeat binding factor 2 (TERF2) in human tumors and in vitro validation in gastric cancer by TERF2 knockdown
Background Telomeric repeat binding factor 2 (TERF2), a key component of the Shelterin complex, is crucial for maintaining telomere integrity and genome stability. While the involvement of TERF2 in tumorigenesis and progression has been documented, comprehensive pan-cancer analyses of TERF2 across different malignancies remain scarce. Methods In the present study, the expression, mutations, immune cell infiltration, and interacting genes of TERF2 were systematically evaluated through bioinformatics analysis, and in vitro experiments were performed to elucidate the functional roles of TERF2 in gastric cancer. Results The findings revealed that TERF2 was predominantly upregulated in cholangiocarcinoma (CHOL), diffuse large B-cell lymphoma (DLBC), pancreatic adenocarcinoma (PAAD), stomach adenocarcinoma (STAD), and thymoma (THYM), correlating with tumor progression. Amplification and mutations were identified as the primary alterations of TERF2, particularly associated with liver hepatocellular carcinoma (LIHC). Furthermore, TERF2 expression was linked to the infiltration of cancer-associated fibroblasts and immune cells in certain cancer types. Protein–protein interaction (PPI) analysis highlighted several genes associated with TERF2, including CTCF, DDX19A, MATR3, ZFP1, and ZFP90. Additionally, in vitro experiments demonstrated that TERF2 knockdown significantly suppressed the proliferation and migration of gastric cancer cells. Conclusions These results suggest that dysregulation and mutations of TERF2 are prevalent across various cancers, contributing to tumor immunity and acting as an oncogenic factor, thus positioning TERF2 as a potential therapeutic target in cancer treatment.
- 22 February 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (3) , 1-14
STM2457 impairs the proliferation of esophageal squamous cell carcinoma by activating DNA damage response through ATM-Chk2 axis
METTL3 has been proven to play an important role in the proliferation of Esophageal squamous cell carcinoma (ESCC). In this study, we focused on investigating the therapeutic role and molecular mechanism of STM2457 in ESCC, which is a novel small-molecule inhibitor of METTL3. The effect of STM2457 on ESCC was evaluated using ESCC cell lines by the cell viability measurement, cloning formation assay, scratching assay, transwell assay, and flow cytometry techniques. Furthermore, the molecular mechanism study was employed to evaluate by RT-qPCR, Western blotting, proteomics analysis, comet assay, etc. Additionally, the anticancer effect of STM2457 was carried out by nude mice tumor xenograft in vivo. This study showed STM2457 could significantly inhibit the proliferation and migration of Eca109 and KYSE150 cells, which promoted G0/G1 phase arrest and apoptosis in a dose-dependent manners in vitro. Moreover, proteomics analysis suggested the important role of ATM in action mechanism of STM2457. Further studies showed that STM2457 may activate DNA damage response and the expression of ATM, p-ATM, p-Chk2, and γ-H2AX protein in ATM-Chk2 pathway. Intriguingly, ATM inhibitor CGK-733 and knocking down ATM significantly reduced the expression of ATM in Eca109 and KYSE150 cells treated with STM2457. Importantly, STM2457 significantly upregulated the expression of ATM and γ-H2AX protein and inhibited the growth of ESCC in vivo. Finally, STM2457 combined with PTX could also significantly inhibit the proliferation and migration ability of Eca109 and KYSE150 cells by targeting the ATM-mediated DDR pathway. In tumor-bearing nude mice model, STM2457 combined with Paclitaxel can inhibit the growth of ESCC and increased the expression of ATM and γ-H2AX protein. These findings revealed ATM-Chk2 pathway is a promising therapeutic target for STM2457 to effectively inhibit the proliferation of ESCC.
- 22 February 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (3) , 1-14
STM2457 impairs the proliferation of esophageal squamous cell carcinoma by activating DNA damage response through ATM-Chk2 axis
METTL3 has been proven to play an important role in the proliferation of Esophageal squamous cell carcinoma (ESCC). In this study, we focused on investigating the therapeutic role and molecular mechanism of STM2457 in ESCC, which is a novel small-molecule inhibitor of METTL3. The effect of STM2457 on ESCC was evaluated using ESCC cell lines by the cell viability measurement, cloning formation assay, scratching assay, transwell assay, and flow cytometry techniques. Furthermore, the molecular mechanism study was employed to evaluate by RT-qPCR, Western blotting, proteomics analysis, comet assay, etc. Additionally, the anticancer effect of STM2457 was carried out by nude mice tumor xenograft in vivo. This study showed STM2457 could significantly inhibit the proliferation and migration of Eca109 and KYSE150 cells, which promoted G0/G1 phase arrest and apoptosis in a dose-dependent manners in vitro. Moreover, proteomics analysis suggested the important role of ATM in action mechanism of STM2457. Further studies showed that STM2457 may activate DNA damage response and the expression of ATM, p-ATM, p-Chk2, and γ-H2AX protein in ATM-Chk2 pathway. Intriguingly, ATM inhibitor CGK-733 and knocking down ATM significantly reduced the expression of ATM in Eca109 and KYSE150 cells treated with STM2457. Importantly, STM2457 significantly upregulated the expression of ATM and γ-H2AX protein and inhibited the growth of ESCC in vivo. Finally, STM2457 combined with PTX could also significantly inhibit the proliferation and migration ability of Eca109 and KYSE150 cells by targeting the ATM-mediated DDR pathway. In tumor-bearing nude mice model, STM2457 combined with Paclitaxel can inhibit the growth of ESCC and increased the expression of ATM and γ-H2AX protein. These findings revealed ATM-Chk2 pathway is a promising therapeutic target for STM2457 to effectively inhibit the proliferation of ESCC.
- Open Access
RNA Binding Protein PTBP1 Promotes the Metastasis of Gastric Cancer by Stabilizing PGK1 mRNA
Gastric cancer (GC) is the most common type of malignant tumor within the gastrointestinal tract, and GC metastasis is associated with poor prognosis. Polypyrimidine tract binding protein 1 (PTBP1) is an RNA-binding protein implicated in various types of tumor development and metastasis. However, the role of PTBP1 in GC metastasis remains elusive. In this study, we verified that PTBP1 was upregulated in GC tissues and cell lines, and higher PTBP1 level was associated with poorer prognosis. It was shown that PTBP1 knockdown in vitro inhibited GC cell migration, whereas PTBP1 overexpression promoted the migration of GC cells. In vivo, the knockdown of PTBP1 notably reduced both the size and occurrence of metastatic nodules in a nude mice liver metastasis model. We identified phosphoglycerate kinase 1 (PGK1) as a downstream target of PTBP1 and found that PTBP1 increased the stability of PGK1 by directly binding to its mRNA. Furthermore, the PGK1/SNAIL axis could be required for PTBP1’s function in the promotion of GC cell migration. These discoveries suggest that PTBP1 could be a promising therapeutic target for GC.
Open AccessRNA Binding Protein PTBP1 Promotes the Metastasis of Gastric Cancer by Stabilizing PGK1 mRNA
Gastric cancer (GC) is the most common type of malignant tumor within the gastrointestinal tract, and GC metastasis is associated with poor prognosis. Polypyrimidine tract binding protein 1 (PTBP1) is an RNA-binding protein implicated in various types of tumor development and metastasis. However, the role of PTBP1 in GC metastasis remains elusive. In this study, we verified that PTBP1 was upregulated in GC tissues and cell lines, and higher PTBP1 level was associated with poorer prognosis. It was shown that PTBP1 knockdown in vitro inhibited GC cell migration, whereas PTBP1 overexpression promoted the migration of GC cells. In vivo, the knockdown of PTBP1 notably reduced both the size and occurrence of metastatic nodules in a nude mice liver metastasis model. We identified phosphoglycerate kinase 1 (PGK1) as a downstream target of PTBP1 and found that PTBP1 increased the stability of PGK1 by directly binding to its mRNA. Furthermore, the PGK1/SNAIL axis could be required for PTBP1’s function in the promotion of GC cell migration. These discoveries suggest that PTBP1 could be a promising therapeutic target for GC.